clinical trial · NCT07619118
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia
Hypercholesterolaemialaroprovstat/rosuvastatin 1laroprovstat/rosuvastatin 2laroprovstat/rosuvastatin 3laroprovstat/rosuvastatin 4Placebo to match laroprovstat/rosuvastatin 1,2,3Placebo to match laroprovstat/rosuvastatin 4Rosuvastatin 1Rosuvastatin 2
brief summary
The purpose of this study is to evaluate the effect on low-density lipoprotein-cholesterol (LDL-C) and the safety and tolerability of a fixed dose combination (FDC) of laroprovstat/rosuvastatin versus rosuvastatin alone in patients with hypercholesterolaemia with either a history of a clinical atherosclerotic cardiovascular disease (ASCVD) event or at increased risk for a first clinical ASCVD event.
started
Sep 10, 2026
primary completion
May 28, 2027
completion
May 28, 2027
last updated
Oct 5, 2026
official title
A Phase III Randomised, Double-Blind, Parallel-Group Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Rosuvastatin on Low-Density Lipoprotein Cholesterol in Patients With Hypercholesterolaemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol